[{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Padagis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Padagis","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Padagis"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Blueberry Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Blueberry Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Terbinafine HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : MOB-015 is a topical formulation of terbinafine which is approved for the treatment of mild to moderate fungal infections in nail and nail bed(Onychomycosis).

                          Product Name : MOB-015

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Terbinafine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : MOB-015 is a topical formulation of terbinafine which is approved for the treatment of mild to moderate fungal infections in nail and nail bed(Onychomycosis).

                          Product Name : MOB-015

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Terbinafine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance.

                          Product Name : BB2603

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 13, 2023

                          Lead Product(s) : Terbinafine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : MOB-015 (terbinafine) is an in-house developed topical formulation, which is investigated for the treatment of onychomycosis and Topline results are expected in January 2025.

                          Product Name : MOB-015

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 10, 2023

                          Lead Product(s) : Terbinafine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.

                          Product Name : MOB-015

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 08, 2022

                          Lead Product(s) : Terbinafine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Padagis

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.

                          Product Name : BB2603

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 28, 2020

                          Lead Product(s) : Terbinafine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank